Drugs / NVX-508
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03013426 | Jul → Dec 2018 | sickle cell disease | Amma Owusu-Ansah, MD | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NVX-508 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03013426 ↗ |
| Modality | Other / unclassified | “NVX-508 is a liquid fluorocarbon which transports oxygen.” NCT03013426 ↗ |
| Route | Intravenous | “Administration of NVX-508 emulsion intravenously” NCT03013426 ↗ |